Close

Applied DNA Sciences (APDN), Evvivax announce positive preliminary Phase I clinical trial results for a LinearDNA COVID-19 vaccine candidate

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. LRCX
3. CMG
4. IBM
5. HCP
6. SPY
7. PI
8. BSX
9. BIIB
10. NOW


Go back to Applied DNA Sciences (APDN), Evvivax announce positive preliminary Phase I clinical trial results for a LinearDNA COVID-19 vaccine candidate

Applied DNA and Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial for LinearDNA™ COVID-19 Vaccine Candidate in Felines

April 12, 2021 1:15 PM EDT

- Vaccine Candidate Well Tolerated and Effective in Cohort -

- Strong Neutralizing Antibody Titer Elicited Across Cohort -

STONY BROOK, N.Y. & ROME--(BUSINESS WIRE)-- Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in Polymerase Chain Reaction (PCR)-based DNA... More